Beleave’s New Research License Allows for Further Optimization of Cannabinoids for Capsules and Edibles

Toronto, Ontario–(Newsfile Corp. – August 13, 2019) – Beleave Inc. (CSE: BE) (OTCQX: BLEVF) (“Beleave” or the “Company“) is pleased to announce that on Friday, August 9, 2019, the Company’s wholly-owned subsidiary Beleave Kannabis Corp was issued a Research License (“License“) under the Cannabis Act and Cannabis Regulations of Canada. All research conducted under this License will be based on research protocols involving the further optimization and validation of methods for formulating cannabinoid compounds for oral ingestion.

“With the emergence of new classes of cannabis products later this year, more at


Leave a Reply